fund manager Capital of Ysios Ha He founded his first company. This company specializes biotechnology investments co-led an operation that became one of the main capitalist partners One Dutch company project, kinexiswhat you have A treatment against cognitive impairment associated with schizophrenia. Part of the deal includes a 57 million euro investment, a capital injection from the Spanish firm Ysioslike forbion (Investment fund specialized in financing companies in the Netherlands) life sciences He would also co-found Kynexis) and to a lesser extent Sunstone Life Science Initiatives.
As the Barcelona-based investment firm explains and Saint SebastianSchizophrenia affects 24 million people worldwide and those who suffer from the condition, among many other things, loss of memory And Difficulty concentrating, completing activities, understanding, remembering, following instructions, and solving problems. According to Ysios’ calculations, seven out of ten patients with schizophrenia have such symptoms, but there is no specific treatment for it.
Given this scenario, kinexis He is exploring the properties of precision medicine to try to interfere with one of the key enzymes in this process. Since this treatment, as it is called in technical jargon, is recommended KYN5356Your goal will be Inhibits the enzyme kynurenine aminotransferase II (KAT-II)a molecule that plays a key role in cognitive functions and such effects of schizophrenia. “Its modulation has the potential to treat cognitive impairments in affected patients and significantly improve their quality of life,” explains Ysios.
This fund manager and his Dutch partner, licence A group company of this potential drug MitsubishiThey then officially incorporated the company and created an expert management team.
“Kynexis has potential Transform the schizophrenia treatment paradigm by addressing cognitive impairmentsan unmet, extremely common and prohibitive medical need: the strength of the scientific data supporting its approach, together with its experienced management team, is undoubtedly key to realizing the potential of its precision medicine-based approach,” said one of the Fund’s partners. Raul Martin Ruiz. “We are very proud to have contributed to the formation of the company and the structuring of a senior international management team,” he adds.